MDT-AP-2032
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- new_clusters
- C2
- umap1_2d
- 1.715927851
- umap2_2d
- 0.773899099
- umap1_3d
- -1.098727082
- umap2_3d
- -1.41947963
- umap3_3d
- -0.509928497
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.710
- MYC_TARGETS_V1+0.500
- OXIDATIVE_PHOSPHORYLATION+0.410
- UNFOLDED_PROTEIN_RESPONSE+0.360
- MYOGENESIS+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- ADIPOGENESIS+0.220
- ANGIOGENESIS+0.220
- MTORC1_SIGNALING+0.220
- FATTY_ACID_METABOLISM+0.190
Top 10 suppressed
- MITOTIC_SPINDLE-0.480
- G2M_CHECKPOINT-0.430
- E2F_TARGETS-0.420
- INTERFERON_ALPHA_RESPONSE-0.360
- COMPLEMENT-0.320
- INTERFERON_GAMMA_RESPONSE-0.310
- NOTCH_SIGNALING-0.310
- HEDGEHOG_SIGNALING-0.280
- APICAL_SURFACE-0.230
- UV_RESPONSE_DN-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BB-A5HZ-01A-21R-A28V-07 | — | — | 0.817 |
| 2 | R20 | — | — | 0.705 |
| 3 | MNG999 | — | — | 0.700 |
| 4 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.681 |
| 5 | MDT-AP-1338 | Med | Medulloblastoma | 0.680 |
| 6 | TCGA-JL-A3YX-01A-11R-A22U-07 | — | B | 0.679 |
| 7 | MNG1050 | — | — | 0.673 |
| 8 | AUR-AG0J-TTM1-A-1-0-R-A743-41 | — | E | 0.670 |
| 9 | e84aa97b-e429-4994-acef-2b57be71fe9a | — | — | 0.665 |
| 10 | aMVAC.P_013_TURBT_S232 | — | — | 0.665 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.710 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.410 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.360 | Idelalisib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| PEROXISOME | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.080 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.040 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.030 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |